Literature DB >> 8946153

Beta-cell dysfunction in first-degree relatives of patients with non-insulin-dependent diabetes mellitus.

M Fernández-Castañer1, J Biarnés, I Camps, J Ripollés, N Gómez, J Soler.   

Abstract

To analyse the relationship between age, glucose tolerance, beta-cell function, and insulin sensitivity in preclinical states of non-insulin-dependent (Type 2) diabetes mellitus (NIDDM), we have done a cross-sectional, age-stratified analysis of 86 non-diabetic first-degree relatives of NIDDM patients and 49 controls with similar age, sex, and BMI. A 5 mg kg ideal body weight-1 min-1 for 60 min of continuous infusion of glucose with model assessment (CIGMA) of serum glucose and C-peptide values at the end of the infusion was used to determine glucose tolerance and beta-cell function. Insulin sensitivity was estimated by modelling basal serum glucose and insulin values. Relatives and controls were divided into tertiles on the basis of age. Relatives had higher basal (5.3 vs 5 mmol l-1, p = 0.02) and achieved serum glucose (9.1 vs 8.4 mmol l-1, p = 0.01), lower beta-cell function (128 vs 145%, p = 0.007), and lower insulin sensitivity (37 vs 43%, p = 0.002). Beta-cell function declined with age in relatives (from 139% in young subjects to 134% in intermediate subjects and to 111% in older subjects, p = 0.002) and this decline was associated with an increase in basal serum glucose (from 5.1 to 5.3 and to 5.7 mmol l-1, p = 0.000) and achieved glucose (from 8.3 to 9.1 and to 9.3 mmol l-1, p = 0.038), without significant changes in insulin sensitivity. These trends were observed even after the exclusion of subjects with mild glucose intolerance. We conclude that both beta-cell dysfunction and insulin resistance are present in first-degree relatives of NIDDM. The progression of beta-cell dysfunction and glucose intolerance with age suggests that beta-cell dysfunction is the key factor in the apparition and progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946153     DOI: 10.1002/(SICI)1096-9136(199611)13:11<953::AID-DIA257>3.0.CO;2-V

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

1.  Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect.

Authors:  Signe Foghsgaard; Louise Vedtofte; Camilla Andreasen; Emilie S Andersen; Emilie Bahne; Jonatan I Bagger; Jens A Svare; Jens J Holst; Tine D Clausen; Elisabeth R Mathiesen; Peter Damm; Filip K Knop; Tina Vilsbøll
Journal:  Diabetologia       Date:  2017-03-31       Impact factor: 10.122

2.  Dynamic responses to leptin secretagogues in lean, obese, and massively obese men and women.

Authors:  Samuel Dagogo-Jack; Hasan Askari; Gunjan Tykodi; Jianmei Liu; Indira Umamaheswaran
Journal:  Horm Res       Date:  2008-07-29

3.  The markers of inflammation and endothelial dysfunction in correlation with glycated haemoglobin are present in type 2 diabetes mellitus patients but not in their relatives.

Authors:  José Manuel Gómez; Ramon Vila; Pablo Catalina; Juan Soler; Lina Badimón; Manel Sahún
Journal:  Glycoconj J       Date:  2008-03-18       Impact factor: 2.916

4.  Insulin sensitivity and β-cell function in normoglycemic offspring of individuals with type 2 diabetes mellitus: Impact of line of inheritance.

Authors:  Edavan P Praveen; Jayaprakash Sahoo; Madan L Khurana; Bindu Kulshreshtha; Rajesh Khadgawat; Nandita Gupta; Sada Nand Dwivedi; Guresh Kumar; Dorairaj Prabhakaran; Ariachery C Ammini
Journal:  Indian J Endocrinol Metab       Date:  2012-01

5.  The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial.

Authors:  Signe Foghsgaard; Louise Vedtofte; Elisabeth R Mathiesen; Jens A Svare; Lise L Gluud; Jens J Holst; Peter Damm; Filip K Knop; Tina Vilsbøll
Journal:  BMJ Open       Date:  2013-10-30       Impact factor: 2.692

6.  Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes.

Authors:  Marlies de Ligt; Yvonne M H Bruls; Jan Hansen; Marie-Fleur Habets; Bas Havekes; Emmani B M Nascimento; Esther Moonen-Kornips; Gert Schaart; Vera B Schrauwen-Hinderling; Wouter van Marken Lichtenbelt; Patrick Schrauwen
Journal:  Mol Metab       Date:  2018-04-18       Impact factor: 7.422

Review 7.  Plasma glucose concentration and prediction of future risk of type 2 diabetes.

Authors:  Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.